Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases by Wicherts, Dennis A. et al.
ORIGINAL ARTICLE – HEPATOBILIARY TUMORS
Regenerative Nodular Hyperplasia of the Liver Related
to Chemotherapy: Impact on Outcome of Liver Surgery
for Colorectal Metastases
Dennis A. Wicherts, MD
1,4, Robbert J. de Haas, MD
1,4, Myle `ne Sebagh, MD
2, Oriana Ciacio, MD
1,
Francis Le ´vi, MD, PhD
3,6,7, Bernard Paule, MD
1,3, Sylvie Giacchetti, MD
3,8, Catherine Guettier, MD, PhD
2,5,7,
Daniel Azoulay, MD, PhD
1,9, Denis Castaing, MD
1,5,7, and Rene ´ Adam, MD, PhD
1,5,7
1Centre He ´pato-Biliaire, AP-HP Ho ˆpital Paul Brousse, Villejuif, France;
2Department of Pathology, AP-HP Ho ˆpital Paul
Brousse, Villejuif, France;
3Department of Medical Oncology, AP-HP Ho ˆpital Paul Brousse, Villejuif, France;
4Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands;
5Inserm, Unite ´ 785, Villejuif,
France;
6Laboratoire ‘Rythmes biologiques et cancers’ Unite ´ 776, Inserm, Villejuif, France;
7Universite ´ Paris-Sud, UMR-S
785, Villejuif, France;
8Department of Medical Oncology, AP-HP Ho ˆpital Saint-Louis, Paris, France;
9Inserm, Unite ´ 1004,
Villejuif, France
ABSTRACT
Background. Regenerative nodular hyperplasia (RNH)
represents the end-stage of vascular lesions of the liver
induced by chemotherapy. The goal was to evaluate its
incidence and impact on the outcome of patients resected
for colorectal liver metastases (CLM).
Methods. Patients who underwent hepatectomy for CLM
after six cycles or more of ﬁrst-line chemotherapy, between
January 1990 and November 2006, were included. Detailed
histopathologic analysis of the nontumoral liver was per-
formed according to a standard format.
Results. From a cohort of 856 resected patients at our
institution, 771 (90%) received preoperative chemotherapy.
Of these, 146 fulﬁlled the selection criteria and were
included: 24 (16%) received 5-ﬂuorouracil (5-FU) and
leucovorin (LV) alone, 92 (63%) had 5-FU/LV and oxa-
liplatin, 18 (12%) had 5-FU/LV and irinotecan, and 12
(8%) were treated by 5-FU/LV, oxaliplatin, and irinotecan.
RNH occurred in 22 of 146 patients (15%). Twenty of
these patients (91%) received oxaliplatin, of whom six
(30%) had chronomodulated therapy. Patients treated by
oxaliplatin more often had RNH compared with oxalipla-
tin-naı ¨ve patients (22 vs. 4%). Although operative
mortality was nil, the presence of RNH was associated with
increased postoperative hepatic morbidity (50 vs. 29%).
Elevated preoperative gamma-glutamyltransferase (GGT)
([80 U/L; [1N) and total bilirubin levels ([15 lmol/L;
[1N) were independent predictors of RNH.
Conclusions. Patients with CLM who receive preoperative
oxaliplatin have an increased risk of RNH and associated
postoperative morbidity. Increased serum GGT and bili-
rubin are useful markers to predict the presence of RNH.
During recent years, the intensity of preoperative sys-
temic chemotherapy for patients with colorectal liver
metastases (CLM) has increased signiﬁcantly. Patients with
unresectable metastatic disease frequently receive pro-
longed chemotherapy treatment in an attempt to convert
them to resectability. With this approach, long-term sur-
vival can be achieved when liver resection becomes
feasible after tumoral downsizing.
1 In addition, neoadju-
vant chemotherapy is applied for resectable liver
metastases to facilitate margin-free resections, and this
approach has shown recently to improve progression-free
survival after hepatectomy.
2,3
Ourgroupandothershavereportedarelationshipbetween
the use of preoperative chemotherapy and histopathologic
changes of the nontumoral liver with consequently an
increased risk of perioperative morbidity.
3–11 This mainly
concerns the prolonged use of oxaliplatin and associated
vascularlesions.However,closeevaluationofdirectrelations
between speciﬁc vascular lesions and postoperative outcome
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3,6–15 Only three studies have cor-
relatedspeciﬁc chemotherapy-relatedvascularchanges inthe
nontumoral liver with an increased intraoperative transfusion
rate or longer hospital stay.
8–10
Regenerative nodular hyperplasia (RNH) is considered
the end-stage of vascular lesions induced by chemotherapy,
but its effect on the outcome of hepatic resection for
colorectal metastases remains unclear. However, with the
increasing indications of preoperative chemotherapy,
especially oxaliplatin, RNH is observed more frequently,
necessitating an evaluation of its consequences. Further-
more, with the high incidence of recurrences observed in
patients resected of CLM, repeat hepatectomies are
increasingly performed.
16–18 Knowledge concerning the
consequences of RNH, as well as its potential to regress, is
crucial in evaluating the risks of repeat surgery with the
continuing administration of chemotherapy.
In this study, we evaluated the incidence of RNH and its
impact on postoperative outcome in patients resected of
CLM. In addition, we assessed the evolution of RNH by
analyzing the pathological specimens of patients submitted
to repeat hepatectomy.
PATIENTS AND METHODS
Patients
From January 1990 to November 2006, 856 consecutive
patients underwent partial hepatectomy for colorectal
metastases at our institute; 771 (90%) of these patients
were treated by preoperative chemotherapy, whereas 85
patients (10%) underwent hepatic resection without pre-
operative chemotherapy treatment. Of all 771 patients
treated by preoperative chemotherapy, this study focused
only on patients who received six or more cycles of ﬁrst-
line therapy. In addition, patients treated with preoperative
intra-arterial chemotherapy were excluded.
Preoperative Chemotherapy
Chemotherapy was most often administered before
surgery for patients with initially unresectable metastases.
Technical unresectability was deﬁned as the inability to
completely resect all metastases while leaving at least 30%
of normal liver parenchyma, resulting from a multinodular
TABLE 1 Review of publications evaluating the effect of preoperative chemotherapy and hepatic chemotoxicity on short-term outcome after
resection of colorectal liver metastases
Author Year No. of
patients
a
Type of
chemotherapy
Related histology
nontumoral liver
Short-term perioperative outcome
Studies of no effect
Parikh
12 2003 61 Irinotecan Steatosis Unaffected
Hewes
13 2007 46 Miscellaneous
b None Unaffected
Pawlik
14 2007 153 Oxaliplatin Sinusoidal dilatation Unaffected
Irinotecan Steatosis/steatohepatitis Unaffected
Scoggins
15 2009 112 Miscellaneous
c None Unaffected
Studies of effect—outcome related to chemotherapy
Karoui
6 2006 45 Miscellaneous
d Sinusoidal dilatation Increased morbidity
Nordlinger
3 2008 151 Oxaliplatin Not analyzed Increased morbidity
Studies of effect—outcome related to liver histology
Vauthey
7 2006 248 Oxaliplatin Sinusoidal dilatation Unaffected
Irinotecan Steatohepatitis Increased 90-day mortality
Aloia
8 2006 75 Oxaliplatin HCN/RNH Increased transfusion rate
Mehta
9 2007 130 Oxaliplatin Sinusoidal dilatation Longer hospital stay and increased
transfusion rate
Nakano
10 2008 90 Oxaliplatin Sinusoidal injury Longer hospital stay and increased
morbidity
e
Kandutsch
11 2008 50 Oxaliplatin Fibrosis Increased transfusion rate
Sinusoidal dilatation Unaffected
HCN hemorrhagic centrilobular necrosis, RNH regenerative nodular hyperplasia
a Treated with preoperative chemotherapy
b 5-Fluorouracil and leucovorin alone or combined with oxaliplatin
c 5-Fluorouracil with various combinations of other agents
d 5-Fluorouracil and leucovorin alone or combined with oxaliplatin, irinotecan or both
e In patients who underwent major hepatectomy (C3 segments)
660 D. A. Wicherts et al.tumor distribution, large tumor size, or a close relationship
with major vascular or biliary structures. The presence of
extrahepatic metastases determined oncological unresec-
tability. The rationale to administer preoperative
chemotherapy to patients with upfront resectable metasta-
ses was to assess tumor chemoresponsiveness and to
facilitate margin-negative resections.
Response to chemotherapy was evaluated in a multi-
disciplinary meeting with surgeons, oncologists, and
radiologists, and surgery was only performed when the
overall strategy could result in complete intra- and extra-
hepatic tumor clearance.
Liver Resection
The goal of liver surgery was to resect completely all
detectable lesions. Detailed inspection, palpation, and
intraoperative ultrasound of the liver were routinely per-
formed in each patient. Local ablation, portal vein
embolization, and two-stage hepatectomy were used as
described before to increase the possibility of radical tumor
resection.
19–21 General and local hepatic complications
occurring within 2 months after surgery were recorded and
classiﬁed.
22,23
Histopathologic Examination
Detailed histopathologic assessment of the nontumoral
liver was performed by a single hepatobiliary pathologist,
blinded for the information regarding preoperative che-
motherapy and perioperative outcome. Liver tissue was
analyzed according to a standard format previously
described.
8 Brieﬂy, vascular lesions were categorized as
sinusoidal alterations (vasodilatation and congestion),
peliosis, hemorrhagic centrilobular necrosis (HCN), RNH,
and veno-occlusive disease. The presence of macrovacuo-
lar steatosis was graded as mild (\30% of hepatocytes),
moderate (30–60%), or severe ([60%). Steatohepatitis
included steatosis with signs of local inﬂammation and
apoptotic hepatocytes. Fibrosis was divided into portal
ﬁbrosis, porto-portal ﬁbrosis, septal ﬁbrosis, and cirrhosis.
Surgical necrosis also was noted.
Repeat Surgery
The development of recurrences was assessed by phys-
ical examination, serum CEA and CA 19.9 levels, and
abdominal ultrasound at 4-month intervals after hepatec-
tomy. CT imaging of the chest, abdomen, and pelvis was
performed every 8 months. Repeat resection of intra- and/
or extrahepatic recurrences was only considered if it could
be macroscopically complete.
17 For patients who under-
went repeat liver surgery, histopathologic examination of
the nontumoral liver was performed in a similar way as
described above to evaluate the evolution of initial lesions.
Statistical Analysis
All statistical analyses were performed using SPSS

software version 13.0 (SPSS Inc., Chicago, IL). Categori-
cal data were reported as the number of patients with
percentages and compared by the v
2 test. For continuous
data, reported as means ± standard deviation, the inde-
pendent-samples t test was used to compare groups.
Logistic regression was done to deﬁne independent pre-
dictive factors of hepatic morbidity as well as preoperative
predictive factors of RNH. Factors with P B 0.10 at uni-
variate analysis were included. P values B0.05 were
considered signiﬁcant.
RESULTS
Of all 771 consecutively resected patients treated by
preoperative chemotherapy, 155 received six or more cycles
of ﬁrst-line therapy, delivered by intravenous route. Due to
an insufﬁcient amount of nontumoral liver parenchyma
available for histopathological analysis, 9 patients were
excluded, resulting in a cohort of 146 patients (Fig. 1).
Patient and Tumor Characteristics
Included patients had a median age of 61 (range, 34–79)
years and 76% presented with synchronous liver metastases
(Table 2). Most patients (54%) had [3 metastases at
diagnosis with a median diameter of 40 (range, 6–160)
mm. Metastases were located in both liver lobes in 70% of
patients and 20 patients (14%) had concomitant extrahe-
patic disease.
Preoperative Chemotherapy
Chemotherapy was indicated for initially unresectable
metastases in the majority of patients (72%). Unresecta-
bility was related to multinodular disease (59%), large
tumor size (29%), close vascular relationship (10%), and
extrahepatic disease (3%). The remaining 28% of patients
received preoperative chemotherapy for resectable disease.
The median number of administered cycles for the total
group was 8 (range, 6–21) and chemotherapy delivery was
chronomodulated in 41% of patients.
24 Twenty-four
patients (16%) received 5-ﬂuorouracil (5-FU) and leuco-
vorin (LV) alone (9.0 ± 2.0 cycles), 92 patients (63%) had
5-FU/LV and oxaliplatin (8.6 ± 2.8 cycles), 18 patients
(12%) had 5-FU/LV and irinotecan (8.9 ± 3.0 cycles), and
12 patients (8%) were treated by 5-FU/LV, oxaliplatin, and
RNH and Outcome of Liver Surgery 661irinotecan (9.6 ± 3.6 cycles). The number of chemother-
apy cycles did not differ between different regimens
(P = 0.70).
Hepatectomy Characteristics
Major hepatectomies (C3 segments) were performed in
50% of patients (Table 2). Red blood cell transfusions were
required in 41% of patients, of whom 94% needed more
than 1 unit of blood. Postoperative morbidity occurred in
43% of patients and one patient (1%) died within 60 days
after surgery. Hepatic complications were classiﬁed as
grade III or IV complications in 34% of patients. Median
duration of hospital stay was 11 (range, 6–42) days.
Nontumoral Liver Parenchyma
Vascular liver lesions constituted the most frequent type
of histopathological lesion and were present in 82 patients
(56%; Table 2). Peliosis was most often observed (31%).
RNH occurred in 22 of 146 patients (15%) and was more
frequent than sinusoidal alterations (11%; Fig. 2). Of note,
steatohepatitis occurred in only one patient (1%).
RNH Versus Non-RNH Patients
Patients with RNH more often presented with [3
metastases at diagnosis compared with patients without
RNH (78 vs. 50%; P = 0.03; Table 3). Twenty RNH
patients (91%) preoperatively received 5-FU/LV and oxa-
liplatin (9.2 ± 2.6 cycles). The two remaining patients
were treated by 5-FU/LV and irinotecan (12 cycles;
N = 1) and 5-FU/LV, oxaliplatin, and irinotecan (6 cycles;
N = 1). Chemotherapy was chronomodulated in six
patients (27%; all oxaliplatin). RNH occurred in 22% of
patients treated by oxaliplatin compared with 4% of
oxaliplatin-naı ¨ve patients (P = 0.003). The number of
chemotherapy cycles was not increased in RNH patients
compared with the control group (9.1 ± 2.7 vs. 8.8 ± 2.8;
P = 0.55).
RNH patients had lower platelet counts at hospital
admission (B150 9 10
3/lL: 48 vs. 17%; P = 0.002).
Mean alkaline phosphatase, gamma-glutamyltransferase
(GGT), and total bilirubin levels before surgery were
higher in RNH patients (Table 3).
Major hepatectomies were performed in a similar per-
centage of patients with and without RNH (55 vs. 49%,
respectively; P = 0.64; Table 3). None of the RNH
patients died within 60 days postoperatively. However,
hepatic complications occurred in 50% of RNH patients
compared with 29% of patients without RNH (P = 0.05).
This difference was mainly caused by an increased inci-
dence of biliary leaks (27 vs. 0%).
Uni- and Multivariate Analysis of Hepatic Morbidity
Seven factors, including RNH, were associated with
hepatic morbidity at univariate analysis (Table 4). How-
ever, only four factors were independent predictors at
multivariate analysis: a preoperative platelet count of
\150 9 10
3/lL, major hepatectomy, two-stage hepatec-
tomy, and intraoperative red blood cell transfusion.
Predictive Factors of RNH
Multivariate logistic regression analysis identiﬁed ele-
vated preoperative GGT ([80 U/L; [1N) and total
bilirubin levels ([15 lmol/L;[1N) as independent factors
predictive for the presence of RNH. Risk ratios were 6.6
(95% conﬁdence interval (CI), 2–21.4) for GGT
(P = 0.002) and 3.3 (95% CI, 1.1–10.0) for total bilirubin
(P = 0.04).
Total number of first hepatectomies for CLM
(January 1990 - November 2006)
N = 856
Preoperative chemotherapy
N = 771 (90%)
Six or more cycles of
first-line therapy
N = 155
Multiple lines or <6 cycles
N = 616
Sufficient nontumoral liver
parenchyma for analysis
N = 146
Insufficient nontumoral liver
parenchyma for analysis
N = 9
No preoperative chemotherapy
N = 85 (10%)
FIG. 1 Flowchart of patient selection
662 D. A. Wicherts et al.Evolution of RNH Within Time
Fifteen of 82 patients (18%) with vascular changes of
the nontumoral liver at ﬁrst hepatectomy underwent repeat
liver surgery. This included 2 of 22 patients (9%) with
RNH at ﬁrst hepatectomy.
RNH was replaced by HCN at second hepatectomy in
both patients following interruption of oxaliplatin and
subsequent treatment with irinotecan. These patients
received 11 and 12 cycles of irinotecan-based chemother-
apy between both hepatectomies, respectively. No new
cases of RNH were found at repeat hepatectomy in the
remaining cases.
TABLE 2 Characteristics of 146 included patients
Chemotherapy group
(N = 146)
Patients
Mean age ± SD (yr) 59.1 ± 9.5
Male/female ratio 85 (58%)/61 (42%)
Mean body mass index ± SD (kg/m
2) 24.1 ± 3.6
Diabetes mellitus 8 (6%)
Primary tumor
Colon/rectum 114 (79%)/31 (21%)
T stage
1/2 19 (17%)
3/4 92 (83%)
N stage
0 43 (38%)
1/2 70 (62%)
Liver metastases diagnosis
Synchronous
a 111 (76%)
Number
B3 62 (46%)
[3 73 (54%)
Mean maximum size ± SD (mm) 45.2 ± 28.6
Bilobar 102 (70%)
Mean CEA ± SD (ng/mL) 293.2 ± 643.1
Concomitant extrahepatic disease 20 (14%)
Extrahepatic resection 11 (58%)
Hepatectomy
Major resection (C3 segments) 73 (50%)
Resection type
Anatomical 47 (32%)
Nonanatomical 34 (23%)
Both 65 (45%)
Vascular occlusion
No 21 (15%)
Total pedicular 73 (54%)
Vascular exclusion 20 (15%)
Selective 22 (16%)
Combined local ablation
No 129 (88%)
Radiofrequency ablation 10 (7%)
Cryotherapy 7 (5%)
Portal vein embolization 18 (12%)
Two-stage hepatectomy 10 (7%)
Red blood cell transfusions
No 78 (59%)
Yes 54 (41%)
Postoperative outcome
Mortality (B60 days) 1 (1%)
Morbidity 63 (43%)
General complications
b 43 (30%)
TABLE 2 continued
Chemotherapy group
(N = 146)
Hepatic complications 47 (32%)
Biliary leak 3 (6%)
Hemorrhage 2 (4%)
Infected collection 5 (11%)
Noninfected collection 21 (45%)
Liver insufﬁciency
23 8 (17%)
Combination 8 (17%)
Relaparotomy 5 (3%)
Drainage 14 (10%)
Mean hospital stay ± SD (days) 12.9 ± 5.9
Nontumoral liver
Macrovacuolar steatosis (C30%) 12 (8%)
Steatohepatitis 1 (1%)
Fibrosis 69 (47%)
Portal 57 (83%)
Porto-portal 11 (16%)
Septal 0 (0%)
Cirrhosis 1 (1%)
Vascular lesions
c 82 (56%)
Sinusoidal alterations
d 16 (11%)
Peliosis 45 (31%)
HCN 36 (25%)
RNH 22 (15%)
Veno-occlusive disease 18 (14%)
Surgical necrosis 8 (6%)
SD standard deviation, CEA carcinoembryonic antigen, HCN hem-
orrhagic centrilobular necrosis, RNH regenerative nodular hyperplasia
a Synchronous metastases were diagnosed before or within 3 months
after resection of the primary colorectal tumor
b As general complications were considered: pulmonary, cardiovas-
cular, urinary tract, infectious (other than local hepatic) and iatrogenic
complications
c Patients with one or more individual vascular changes
d Vasodilatation or congestion
RNH and Outcome of Liver Surgery 663FIG. 2 Example of regenerative
nodular hyperplasia. Nodules of
hyperplastic hepatocytes replace the
normal liver parenchyma and are
surrounded by atrophic plates without
evidence of ﬁbrosis (note the
hemorrhagic changes close to atrophic
plates). a Gordon and Sweet stain
(920); b Hematoxylin-eosin stain
(910); c Picrosirius stain (920);
d Picrosirius stain (910)
TABLE 3 Characteristics of patients with and without RNH
No RNH
(N = 124)
RNH
(N = 22)
P
Patients
Mean age ± SD (yr) 59.1 ± 9.9 59.1 ± 7.6 0.99
Male/female ratio 73 (59%)/
51 (41%)
12 (55%)/
10 (46%)
0.71
Mean body mass
index ± SD (kg/m
2)
24.0 ± 3.5 24.4 ± 4 0.6
Diabetes mellitus 6 (5%) 2 (10%) 0.43
Liver metastases diagnosis
Synchronous
a 91 (73%) 20 (91%) 0.08
Number
B3 58 (50%) 4 (22%) 0.03
[3 59 (50%) 14 (78%)
Mean maximum
size ± SD (mm)
44.5 ± 28.4 49 ± 30.2 0.52
Bilobar 84 (68%) 18 (82%) 0.19
Preoperative chemotherapy
Chronotherapy 53 (43%) 6 (27%) 0.16
Mean number of
cycles ± SD
8.8 ± 2.8 9.1 ± 2.7 0.55
B9 75 (63%) 12 (55%) 0.45
[9 44 (37%) 10 (46%)
Regimen
5-FU/LV and
oxaliplatin
72 (58%) 20 (91%) 0.003
Other 52 (42%) 2 (9%)
Preoperative biochemical variables
Mean ICG-
R15 ± SD (%)
15 ± 7.3 13 ± 5.7 0.35
TABLE 3 continued
No RNH
(N = 124)
RNH
(N = 22)
P
Mean hemoglobin
level ± SD (g/dL)
12.3 ± 1.5 11.9 ± 1.5 0.27
Mean platelet
count ± SD (10
3/lL)
217.8 ± 74.7 158.7 ± 63.3 0.001
B150 19 (17%) 10 (48%) 0.002
[150 92 (83%) 11 (52%)
Mean prothrombin
time ± SD (%)
90.2 ± 12.2 91.8 ± 8.9 0.59
Mean AST ± SD (U/L) 48 ± 64.7 58.6 ± 36.2 0.46
Mean ALT ± SD (U/L) 46.9 ± 81 60.2 ± 49.6 0.46
Mean AP ± SD (U/L) 133.6 ± 124.7 208.8 ± 154.5 0.03
B100 52 (52%) 2 (12%) 0.002
[100 49 (49%) 15 (88%)
Mean GGT ± SD (U/L) 96.1 ± 125.2 235.2 ± 284.8 \0.001
B80 75 (65%) 4 (20%) \0.001
[80 40 (35%) 16 (80%)
Mean total
bilirubin ± SD
(lmol/L)
11.8 ± 10.1 15 ± 8.5 0.17
B15 100 (86%) 14 (64%) 0.01
[15 16 (14%) 8 (36%)
Hepatectomy
Major resection (C3
segments)
61 (49%) 12 (55%) 0.64
Vascular occlusion
No 20 (17%) 1 (5%) 0.47
Total pedicular 60 (52%) 13 (62%)
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Although previous reports have correlated preoperative
chemotherapy for CLM with increased postoperative
complications, evidence for a direct relation between spe-
ciﬁc nontumoral liver lesions and postoperative morbidity
remains preliminary.
7–10,25,26 With the increasing use of
preoperative chemotherapy, especially oxaliplatin, it is
nevertheless important to know the incidence and impact of
different vascular lesions on postoperative outcome and to
know how these lesions can be predicted to adjust patient
monitoring and to identify patients at risk of increased
morbidity.
Our present study shows that RNH may occur in 15% of
patients treated with preoperative chemotherapy. RNH is
associated with increased hepatic morbidity and occurs
most frequently in patients receiving oxaliplatin. Interest-
ingly, its presence can be predicted preoperatively by
elevated levels of GGT and total bilirubin.
The fact that RNH was related with increased postop-
erative hepatic morbidity was an important ﬁnding of our
study. However, only a preoperative platelet count of
\150 9 10
3/lL, major hepatectomy, two-stage hepatec-
tomy, and intraoperative red blood cell transfusion were
independent predictors of hepatic morbidity at multivariate
analysis in the total study population. Major hepatectomy,
two-stage hepatectomy, and intraoperative red blood cell
transfusions were equally distributed between RNH and
non-RNH patients. However, RNH patients had relatively
low platelet counts compared with non-RNH patients. We
may assume that a low platelet count was related to
splenomegaly due to portal hypertension caused by RNH,
with subsequent platelet trapping. These results all
strengthen the association of RNH with increased hepatic
morbidity observed in our study.
In a recent study, sinusoidal liver injury was related with
increased morbidity after major hepatectomy for CLM
after preoperative chemotherapy.
10 Our inclusion of both
minor and major hepatectomies conﬁrms the importance of
recognizing RNH in all patients scheduled for hepatectomy
after preoperative chemotherapy treatment. Furthermore,
our result was independent of the number of chemotherapy
cycles.
Interestingly, we identiﬁed preoperative elevated levels
of GGT and total bilirubin as predictive factors of RNH. A
recent study also found that high levels of GGT predicted
the presence of sinusoidal lesions.
27 Surprisingly, mean
ICG-R15 values, known to be more sensitive and reliable
for hepatic injury, were not altered in our patients with
RNH. For patients at risk for RNH, efforts should be made
to reduce the risks of liver surgery. Techniques, such as
portal vein embolization and two-stage hepatectomy, may
be helpful to spare the highest amount of liver parenchyma
as possible, thereby maximizing the chances of an
uneventful postoperative course.
In relation with the increased risk of hepatic morbidity
and the enlarging number of patients who undergo repeat
hepatectomy with perioperative chemotherapy, it is
important to consider the evolution of RNH within time.
RNH may have deleterious long-term consequences related
to the development of portal hypertension. One case study
reported the development of RNH and portal hypertension
in three patients treated with oxaliplatin that ﬁnally
TABLE 3 continued
No RNH
(N = 124)
RNH
(N = 22)
P
Vascular exclusion 16 (14%) 4 (19%)
Selective 19 (17%) 3 (14%)
Portal vein embolization 13 (11%) 5 (23%) 0.11
Two-stage hepatectomy 7 (6%) 3 (14%) 0.17
Mean red blood cell
transfusions ± SD
(units)
1.5 ± 2.4 1.4 ± 1.5 0.9
No 68 (61%) 10 (48%) 0.24
Yes 43 (39%) 11 (52%)
Postoperative outcome
Mortality (B60 days) 1 (1%) 0 (0%) 0.67
Morbidity 50 (40%) 13 (59%) 0.1
General complications
b 35 (28%) 8 (36%) 0.44
Hepatic complications 36 (29%) 11 (50%) 0.05
Biliary leak 0 (0%) 3 (27%) 0.04
Hemorrhage 2 (6%) 0 (0%)
Infected collection 4 (11%) 1 (9%)
Noninfected collection 18 (50%) 3 (27%)
Liver insufﬁciency
23 6 (17%) 2 (18%)
Combination 6 (17%) 2 (18%)
Relaparotomy 5 (4%) 0 (0%) 0.34
Drainage 11 (9%) 3 (14%) 0.48
Mean hospital
stay ± SD (days)
12.7 ± 5.7 13.9 ± 7.3 0.36
Nontumoral liver
Sinusoidal alterations
c 13 (11%) 3 (14%) 0.66
Peliosis 38 (31%) 7 (32%) 0.91
HCN 30 (24%) 6 (27%) 0.77
RNH regenerative nodular hyperplasia, SD standard deviation,
ICG-R15 indocyanine green retention rate at 15 minutes, AST
aspartate aminotransferase, ALT alanine aminotransferase, AP alka-
line phosphatase, GGT gamma-glutamyltransferase, HCN hemor-
rhagic centrilobular necrosis
a Synchronous metastases were diagnosed before or within 3 months
after resection of the primary colorectal tumor
b As general complications were considered: pulmonary, cardiovas-
cular, urinary tract, infectious (other than local hepatic) and iatrogenic
complications
c Vasodilatation or congestion
RNH and Outcome of Liver Surgery 665TABLE 4 Univariate and multivariate analysis of hepatic morbidity
Variable N Hepatic morbidity
Yes (N = 47) No (N = 99) UV P MV P RR (95% CI)
Patient factors
Gender
Male 85 25 (53%) 60 (61%) 0.4 – –
Female 61 22 (47%) 39 (39%)
Age at hepatectomy (yr)
B60 78 22 (47%) 56 (57%) 0.27 – –
[60 68 25 (53%) 43 (43%)
Liver metastases
Synchronous
a
No 35 7 (15%) 28 (28%) 0.08 NS –
Yes 111 40 (85%) 71 (72%)
Number
B3 62 17 (43%) 45 (47%) 0.6 – –
[3 73 23 (58%) 50 (53%)
Maximum size (mm)
B30 50 17 (40%) 33 (38%) 0.9 – –
[30 79 26 (61%) 53 (62%)
Localization
Unilobar 44 13 (28%) 31 (31%) 0.65 – –
Bilobar 102 34 (72%) 68 (69%)
Initial resectability
No 105 36 (77%) 69 (70%) 0.39 – –
Yes 41 11 (23%) 30 (30%)
Concomitant extrahepatic disease
No 125 40 (87%) 85 (86%) 0.86 – –
Yes 20 6 (13%) 14 (14%)
Preoperative chemotherapy
No. of cycles
B9 87 26 (57%) 61 (64%) 0.38 – –
[9 54 20 (44%) 34 (36%)
Regimen
5-FU/LV and oxaliplatin 92 33 (70%) 59 (60%) 0.21 – –
Other 54 14 (30%) 40 (40%)
Preoperative biochemical variables
ICG-R15 (%)
B10 22 10 (35%) 12 (21%) 0.19 – –
[10 63 19 (66%) 44 (79%)
Platelet count
a (10
3/lL)
B150 29 13 (33%) 16 (17%) 0.05 0.01 3.5 (1.3–9.2)
[150 103 27 (68%) 76 (83%)
Prothrombin time (%)
B90 50 18 (41%) 32 (36%) 0.58 – –
[90 83 26 (59%) 57 (64%)
AST
a (U/L)
B30 63 16 (36%) 47 (51%) 0.10 NS –
[30 75 29 (64%) 46 (50%)
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Variable N Hepatic morbidity
Yes (N = 47) No (N = 99) UV P MV P RR (95% CI)
ALT (U/L)
B30 76 23 (51%) 53 (57%) 0.52 – –
[30 62 22 (49%) 40 (43%)
AP (U/L)
B100 54 19 (48%) 35 (45%) 0.79 – –
[100 64 21 (53%) 43 (55%)
GGT (U/L)
B80 79 28 (64%) 51 (56%) 0.4 – –
[80 56 16 (36%) 40 (44%)
Total bilirubin (lmol/L)
B15 114 35 (78%) 79 (85%) 0.3 – –
[15 24 10 (22%) 14 (15%)
Hepatectomy
Major resection
a (C3 segments)
No 73 17 (36%) 56 (57%) 0.02 0.05 2.6 (1–6.4)
Yes 73 30 (64%) 43 (43%)
Pedicular clamping
No 43 10 (23%) 33 (36%) 0.12 – –
Yes 93 34 (77%) 59 (64%)
Combined local treatment
No 129 43 (92%) 86 (87%) 0.42 – –
Yes 17 4 (9%) 13 (13%)
Portal vein embolization
No 128 40 (85%) 88 (89%) 0.52 – –
Yes 18 7 (15%) 11 (11%)
Two-stage hepatectomy
a
No 136 41 (87%) 95 (96%) 0.05 0.03 5.7 (1.2–27.2)
Yes 10 6 (13%) 4 (4%)
Intraoperative RBC transfusion
a
No 78 19 (43%) 59 (67%) 0.01 0.03 2.6 (1.1–6.1)
Yes 54 25 (57%) 29 (33%)
Nontumoral liver
Macrovacuolar steatosis (B30%)
No 134 44 (94%) 90 (91%) 0.58 – –
Yes 12 3 (6%) 9 (9%)
Fibrosis
No 77 28 (60%) 49 (50%) 0.25 – –
Yes 69 19 (40%) 50 (51%)
Sinusoidal alterations
No 130 43 (92%) 87 (88%) 0.51 – –
Yes 16 4 (9%) 12 (12%)
Peliosis
No 101 31 (66%) 70 (71%) 0.56 – –
Yes 45 16 (34%) 29 (29%)
HCN
No 109 37 (79%) 72 (74%) 0.49 – –
Yes 36 10 (21%) 26 (27%)
RNH and Outcome of Liver Surgery 667contraindicated curative liver surgery.
28 Recently, the
development of portal hypertension in patients with RNH
with deleterious postoperative complications and even
death was reported by another group.
29 Other reports on
RNH as a result of preoperative chemotherapy are rare.
30
When we evaluated the evolution of vascular lesions in
patients that underwent repeat hepatectomy, previously
diagnosed RNH was replaced by HCN in two patients.
Because RNH is distributed throughout the liver in a
regular pattern, sample variation is unlikely to cause the
absence of RNH at subsequent hepatectomies.
31 Further-
more, all nontumoral liver specimens were evaluated by
the same hepatobiliary pathologist. The natural history of
RNH remains largely unknown.
28 However, because it is
a noncirrhotic liver disease without ﬁbrosis, RNH can
theoretically regress, as was demonstrated in our study.
27
Interestingly, in both patients in whom RNH disap-
peared, oxaliplatin was stopped and irinotecan was
administered before the second hepatectomy. This may
suggest that irinotecan may be a good alternative of
oxaliplatin to treat these patients. Previously, RNH had
already been associated with the use of oxaliplatin.
4
Recently, different authors have suggested a protective
effect of bevacizumab on the development of vascular
toxicity.
32–34 Therefore, its addition to conventional
chemotherapy may reduce the risk of RNH and associ-
ated morbidity. However, this issue lies beyond the
scope of the present study and needs further evaluation.
Conclusions on the evolution of vascular lesions other
than RNH into less or more severe types at repeat
hepatectomy are difﬁcult because of their irregular dis-
tribution throughout the liver with the subsequent risk of
sample variation.
Our study represents a selected patient group that
received only one line of chemotherapy. By this way, we
were able to correlate RNH with different chemotherapy
regimens most accurately. However, with the large amount
of patients receiving multiple chemotherapy regimens
before surgery, RNH may be even more frequent in
daily practice. The potential negative effect of portal
hypertension related to RNH on patient outcome should not
be underestimated.
A ﬁnal interesting remark of our study is that we
observed only one patient with steatohepatitis, who
received oxaliplatin before hepatectomy. Previous large
series have associated steatohepatitis mainly with irino-
tecan, one of whom even found that steatohepatitis was
related with an increased 90-day mortality rate.
7,14 The low
incidence of obese patients and patients with diabetes
probably is one of the reasons for the low frequency of
steatohepatitis in our current study. The precise causes and
consequences of this entity should nevertheless be inves-
tigated more extensively.
CONCLUSIONS
An increasing number of patients with CLM currently
receive oxaliplatin-based chemotherapy, including adju-
vant treatment after stage III colon cancer, induction
therapy to convert extensive metastases to resectability, or
perioperative treatment in patients with resectable metas-
tases.
1,3,35 RNH may occur in one of ﬁve patients, with an
increased risk of postoperative morbidity after hepatec-
tomy. Elevated serum GGT and bilirubin are useful
markers to detect RNH that does not contraindicate hepatic
resection. Clinical recommendations regarding preopera-
tive chemotherapy treatment based on these results should
be evaluated further, taking into account the availability
and consequences of new biological agents.
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